|
1
|
He X, Yang K, Chen P, et al: Arsenic
trioxide-based therapy in relapsed/refractory multiple myeloma
patients: A meta-analysis and systematic review. Onco Targets Ther.
7:1593–1599. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spitzer TR, Sachs DH and Cosimi B:
Multiple myeloma. N Engl J Med. 364:23642011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hussein MA, Saleh M, Ravandi F, et al:
Phase 2 study of arsenic trioxide in patients with relapsed or
refractory multiple myeloma. Br J Haematol. 125:470–476. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanaat Z, Rezazadeh M, Gharamaleki JV, et
al: Arsenic trioxide in patients with refractory multiple myeloma:
A prospective, phase II, single-arm study. Acta Med Iran.
49:504–508. 2011.PubMed/NCBI
|
|
5
|
Rousselot P, Larghero J, Arnulf B, et al:
A clinical and pharmacological study of arsenic trioxide in
advanced multiple myeloma patients. Leukemia. 9:1518–1521. 2004.
View Article : Google Scholar
|
|
6
|
Wu K, van Droogenbroeck J, Beksac M, et
al: Treatment with asenic trioxide, ascorbic acid and dexamethasone
in advanced myeloma patients: Preliminary findings of a
multicenter, phase II study. Blood. 106:367b2005.
|
|
7
|
Berenson JR, Boccia R, Siegel D, et al:
Efficacy and safety of melphalan, arsenic trioxide and ascorbic
acid combination therapy in patients with relapsed or refractory
multiple myeloma: A prospective, multicentre, phase II, single-arm
study. Br J Haematol. 135:174–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertenson J, Marous J, Ferretti D, et al:
A phase I/II trial evaluation the combination of arsenic trioxide,
bortezomib and ascorbic acid for patients with relapsed or
refractory multiple myeloma. Blood. 106:25652005.
|
|
9
|
Matthews GM, Newbold A and Johnstone RW:
Intrinsic and extrinsic apoptotic pathway signaling as determinants
of histone deacetylase inhibitor antitumor activity. Adv Cancer
Res. 116:165–197. 2012.PubMed/NCBI
|
|
10
|
Ye BG, Lin FA, Shen JZ, et al: Synergistic
effects of VPA and As2O3 on Molt-4 cells in
vitro and its possible mechanisms. Zhongguo shi yan xue ye xue za
zhi. 16:1288–1292. 2008.PubMed/NCBI
|
|
11
|
Dimopoulos M, Siegel DS, Lonial S, et al:
Vorinostat or placebo in combination with bortezomib in patients
with multiple myeloma (VANTAGE 088): a multicentre, randomised,
double-blind study. Lancet Oncol. 14:1129–1140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang M, Martin T, Bensinger W, et al:
Phase 2 dose-expansion study (PX-171–006) of carfilzomib,
lenalidomide and low-dose dexamethasone in relapsed or progressive
multiple myeloma. Blood. 122:3122–3128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaufman JL, Fabre C, Lonial S, et al:
Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and
Evidence for Their Use in Combination Therapy. Clin Lymphoma
Myeloma Leuk. 13:370–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Richardson P, Mitsiades C, Colson K, et
al: Phase I trial of oral vorinostat (suberoylanilide hydroxamic
acid, SAHA) in patients with advanced multiple myeloma. Leuk
Lymphoma. 49:502–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galli M, Salmoiraghi S, Golay J, et al: A
phase II multiple dose clinical trial of histone deacetylase
inhibitor ITF2357 in patients with relapsed or progressive multiple
myeloma. Ann Hematol. 89:185–190. 2010. View Article : Google Scholar
|
|
16
|
Niesvizky R, Ely S, Mark T, et al: Phase 2
trial of the histone deacetylase inhibitor romidepsin for the
treatment of refractory multiple myeloma. Cancer. 117:336–342.
2011. View Article : Google Scholar
|
|
17
|
DeAngelo DJ, Spencer A, Bhalla KN, et al:
Phase Ia/II, two-arm, open-label, dose-escalation study of oral
panobinostat administered via two dosing schedules in patients with
advanced hematologic malignancies. Leukemia. 27:1628–1636. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gimsing P, Hansen M, Knudsen LM, et al: A
phase I clinical trial of the histone deacetylase inhibitor
belinostat in patients with advanced hematological neoplasia. Eur J
Haematol. 81:170–176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Richardson PG, Mitsiades CS, Laubach JP,
et al: Preclinical data and early clinical experience supporting
the use of histone deacetylase inhibitors in multiple myeloma. Leuk
Res. 37:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neri P, Tagliaferri P, Di Martino MT, et
al: In vivo anti-myeloma activity and modulation of gene expression
profile induced by valproic acid, a histone deacetylase inhibitor.
Br J Haematol. 143:520–531. 2008.PubMed/NCBI
|
|
21
|
Lengfelder E, Hofmann WK and Nowak D:
Treatment of acute promyelocytic leukemia with arsenic trioxide:
Clinical results and open questions. Expert Rev Anticancer Ther.
13:1035–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berenson JR and Yeh HS: Arsenic compounds
in the treatment of multiple Myeloma: A new role for a historical
remedy. Clin Lymphoma Myeloma. 7:192–198. 2006. View Article : Google Scholar
|
|
23
|
Sanaat Z, Rezazadeh M, Gharamaleki JV, et
al: Arsenic trioxide in patients with refractory multiple myeloma:
A prospective, phase II, single-arm study. Acta Med Iran.
49:504–508. 2011.PubMed/NCBI
|
|
24
|
Held LA, Rizzieri D, Long GD, et al: A
Phase I study of arsenic trioxide (Trisenox), ascorbic acid and
bortezomib (Velcade) combination therapy in patients with
relapsed/refractory multiple myeloma. Cancer Invest. 31:172–176.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanaat Z, Rezazadeh M, Gharamaleki JV, et
al: Arsenic trioxide in patients with refractory multiple myeloma:
a prospective, phase II, single-arm study. Acta Med Iran.
49:504–508. 2011.PubMed/NCBI
|
|
26
|
Sharma M, Khan H, Thall PF, et al: A
randomized phase 2 trial of a preparative regimen of bortezomib,
high-dose melphalan, arsenic trioxide and ascorbic acid. Cancer.
118:2507–2515. 2012. View Article : Google Scholar
|
|
27
|
Takahashi S: Combination therapy with
arsenic trioxide for hematological malignancies. Anticancer Agents
Med Chem. 10:504–510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Röllig C and Illmer T: The efficacy of
arsenic trioxide for the treatment of relapsed and refractory
multiple myeloma: a systematic review. Cancer Treat Rev.
35:425–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng CY, Jiang J, Zheng HT, et al:
Growth-inhibiting effects of arsenic trioxide plus epigenetic
therapeutic agents on leukemia cell lines. Leuk Lymphoma.
51:297–303. 2010. View Article : Google Scholar
|
|
30
|
Qu X, Du J, Zhang C, et al: Arsenic
trioxide exerts antimyeloma effects by inhibiting activity in the
cytoplasmic substrates of histone deacetylase 6. PLoSOne.
7:e322152012. View Article : Google Scholar
|
|
31
|
Selokar NL, St John L, Revay T, et al:
Effect of histone Deacetylase inhibitor Valproic acid treatment on
donor cell growth characteristics, cell cycle arrest, apoptosis and
handmade cloned Bovine Embryo production efficiency. Cell
Reprogram. 15:531–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
